Draft of USP Chapter <711> Dissolution (PDG harmonized document) Published for Comments
Recommendation

Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
In the Pharmacopeial Forum, PF 49(3), a proposal of a revised USP General Chapter <711> Dissolution has been published for comments. The background to the publication is the efforts of international harmonization of monographs and general analytical methods of the European, Japanese, and United States pharmacopeias.
The Pharmacopoeial Discussion Group (PDG)
The Pharmacopoeial Discussion Group (PDG), which was created in 1989, brings together
- the Japanese Pharmacopoeia (JP),
- the European Pharmacopoeia (Ph. Eur.),
- and the United States Pharmacopeia (USP).
The PDG works on pharmacopoeial harmonization of excipient monographs and general chapters.
Revised USP Chapter <711> Dissolution
The now published proposal is based on the version of the USP chapter official since 01 May 2023. It represents the official inquiry stage 2A of Revision 5 to the PDG harmonized document.
According to the briefing notes, the draft includes changes in the following sections:
- "Apparatus, Apparatus 1 (basket apparatus)
- Apparatus 3 (Reciprocating Cylinder)
- Apparatus 4 (Flow-Through Cell)
- Apparatus 4 (Flow-Through Cell), Apparatus Suitability
- Procedure, Apparatus 1 and Apparatus 2, Immediate-Release Dosage Forms
- Procedure, Apparatus 1 and Apparatus 2, Delayed-Release Dosage Forms
- Procedure, Apparatus 3 (reciprocating cylinder), Immediate-Release Dosage Forms, Extended-Release Dosage Forms, and Delayed-Release Dosage Forms
- Procedure, Apparatus 4 (Flow-through Cell), Immediate-Release Dosage Forms, Extended-Release Dosage Forms, and Delayed-Release Dosage Forms
- Interpretation, Immediate-Release Dosage Forms, Acceptance Table 1
- Interpretation, Extended-Release Dosage Forms, Acceptance Table 2
- Interpretation, Delayed-Release Dosage Forms, Acid Stage, Acceptance Table 3, and Buffer Stage, Acceptance Table 4"
The draft of the revised chapter is available on PF Online. The comment period is open from now on until 31 July 2023.
Related GMP News
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
24.06.2026Analytical Quality Group Developments January through April 2026
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation


